

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address COMMISSIONER FOR PATENTS PO Box 1450 Alexascins, Virginia 22313-1450 www.emplo.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.		
10/674,904	09/30/2003	Cecil Kost	MMSI121562	8999		
26389 7590 6600,0008 CHRISTENSEN, O'CONNOR, JOHNSON, KINDNESS, PLLC 1420 FIFTH AVENUE			EXAM	EXAMINER		
			LASTRA, DANIEL			
	SUITE 2800 SEATTLE, WA 98101-2347		ART UNIT	PAPER NUMBER		
,			3688	•		
			MAIL DATE	DELIVERY MODE		
			06/09/2008	PAPER		

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Advisory Action Before the Filing of an Appeal Brief

Application No.	Applicant(s)	
10/674,904	KOST ET AL.	
Examiner	Art Unit	
DANIEL LASTRA	3688	

	DANIEL LASTRA	3000				
The MAILING DATE of this communication appe	ars on the cover sheet with the o	correspondence add	ress			
THE REPLY FILED 28 April 2008 FAILS TO PLACE THIS APPI	LICATION IN CONDITION FOR AL	LOWANCE.				
 The reply was filed after a final rejection, but prior to or on application, applicant must timely file one of the following i application in condition for allowance, (2) a Notice of Appe for Continued Examination (RCE) in compliance with 37 C periods: 	replies: (1) an amendment, affidavi eal (with appeal fee) in compliance	t, or other evidence, w with 37 CFR 41.31; or	hich places the (3) a Request			
a) \(\bigsize \) The period for reply expires 3 months from the mailing date of the final rejection. b) \(\bigsize \) The period for reply expires on: (1) the mailing date of this Advisory Action, or (2) the date set forth in the final rejection, whichever is later. I no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of the final rejection.						
Examiner Note: If box 1 is checked, check either box (a) or (I MONTHS OF THE FINAL REJECTION. See MPEP 706.07(f	b). ONLY CHECK BOX (b) WHEN THE).	FIRST REPLY WAS FI	LED WITHIN TWO			
Extensions of time may be obtained under 37 CFR 1.136(a). The date whave been filled is the date for purposes of determining the period oxtunder 37 CFR 1.17(a) is calculated from: (1) the expiration date of the set forth in (b) above, if checked. Any reply received by the Office later may reduce any earned patient term adjustment. See 37 CFR 1.704(b). NOTICE OF APPEAL.	ension and the corresponding amount of hortened statutory period for reply origing than three months after the mailing date	of the fee. The appropria nally set in the final Office	ate extension fee e action; or (2) as			
2. The Notice of Appeal was filed on 04/28/2008. A brief in o	compliance with 37 CFR 41.37 mus	t be filed within two m	onths of the			
date of filing the Notice of Appeal (37 CFR 41.37(a)), or ar Since a Notice of Appeal has been filed, any reply must be	ny extension thereof (37 CFR 41.37	7(e)), to avoid dismiss	al of the appeal.			
<u>AMENDMENTS</u>						
 The proposed amendment(s) filed after a final rejection, be They raise new issues that would require further cor 			cause			
(a) ☐ They raise new issues that would require further cor (b) ☐ They raise the issue of new matter (see NOTE below		E below);				
(c) They are not deemed to place the application in bett appeal; and/or		lucing or simplifying t	ne issues for			
(d) ☐ They present additional claims without canceling a c	corresponding number of finally reje	cted claims.				
NOTE: (See 37 CFR 1.116 and 41.33(a)).	,					
4. The amendments are not in compliance with 37 CFR 1.12	21. See attached Notice of Non-Cor	mpliant Amendment (I	PTOL-324).			
5. Applicant's reply has overcome the following rejection(s):						
Newly proposed or amended claim(s) would be all non-allowable claim(s).		imely filed amendmer	nt canceling the			
7. For purposes of appeal, the proposed amendment(s): a) how the new or amended claims would be rejected is prov		be entered and an e	xplanation of			
The status of the claim(s) is (or will be) as follows:						
Claim(s) allowed:						
Claim(s) objected to: Claim(s) rejected: <u>1.2,4-10,16-25,31,33-45 and 51-55</u> .						
Claim(s) rejected: 1,2,4-10,16-25,31,33-45 and 51-55. Claim(s) withdrawn from consideration:						
AFFIDAVIT OR OTHER EVIDENCE						
 The affidavit or other evidence filed after a final action, but because applicant failed to provide a showing of good and was not earlier presented. See 37 CFR 1.116(e). 						
 The affidavit or other evidence filed after the date of filing entered because the affidavit or other evidence failed to or showing a good and sufficient reasons why it is necessary 	vercome <u>all</u> rejections under appea	l and/or appellant fail:	s to provide a			
 The affidavit or other evidence is entered. An explanation REQUEST FOR RECONSIDERATION/OTHER 	n of the status of the claims after er	ntry is below or attach	ed.			
11. The request for reconsideration has been considered but See Continuation Sheet.	does NOT place the application in	condition for allowan	ce because:			
12. Note the attached Information Disclosure Statement(s). (PTO/SB/08) Paper No(s)					
13. Other:						
	/Daniel Abana					
	/Raquel Alvarez/ Primary Examiner, Art U	nit 3688				
	i illiary Examiner, Art O	III. 0000				

Continuation of 11, does NOT place the application in condition for allowance because: The Applicant argues that because the Office requires the same words to appear in the specification to support claim limitation, the Office has failed, according to the Applicant, to state a proper 112 rejection. The Examiner answers that Applicant's specification only mentions the term "brand website" in Applicant's specification appear of where it recites "many other personalizations capabilities to tailor the distribution of drug page to prescribers are possible, such as brand website", Applicant's specification does not mention anything else with respect to brand website. Peyrelevade teaches customizing the products presented to a user browsing a website based upon said website branding peragraphs 51-52). Therefore, contrary to Applicant's argument, Peyrelevade teaches Applicant's claimed limitation. The Applicant argues that it is a bizarre interpretation that lipstic or other beauty products can be construed as drug samples. The Examiner answers the Peyrelevade was used by the Examiner to simply teach that it is old and well known in the promotion art to customize the products presented to a user browsing a website branding of said website. Therefore, Pevelevade is relevant to Applicant's claimed interfor's claimed inversity as and the products are becomed as a product on the brand of said website. Therefore, Pevelevade is relevant to Applicant's claimed inversity as all the products are becomed as a product of the products are becomed as a product of the products of the products are becomed as a product of the products of the